Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 472,000 shares, an increase of 9.3% from the March 15th total of 432,000 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average trading volume of 240,200 shares, the short-interest ratio is presently 2.0 days.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock traded up $0.80 during mid-day trading on Monday, reaching $5.49. 261,359 shares of the company's stock traded hands, compared to its average volume of 243,271. Werewolf Therapeutics has a 12 month low of $1.57 and a 12 month high of $8.19. The firm has a 50 day moving average price of $6.33 and a two-hundred day moving average price of $4.26. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14. The firm has a market capitalization of $234.64 million, a PE ratio of -5.05 and a beta of 0.70.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.10. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative net margin of 187.37% and a negative return on equity of 32.25%. On average, research analysts forecast that Werewolf Therapeutics will post -1.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Financial Perspectives Inc boosted its holdings in Werewolf Therapeutics by 80.0% in the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company's stock worth $26,000 after buying an additional 3,000 shares during the period. Rhumbline Advisers raised its position in shares of Werewolf Therapeutics by 16.8% during the 1st quarter. Rhumbline Advisers now owns 22,550 shares of the company's stock valued at $99,000 after buying an additional 3,245 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Werewolf Therapeutics by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 68,338 shares of the company's stock valued at $301,000 after buying an additional 3,555 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Werewolf Therapeutics by 8.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 62,923 shares of the company's stock valued at $243,000 after buying an additional 4,795 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Werewolf Therapeutics by 31.0% during the 2nd quarter. Northern Trust Corp now owns 26,067 shares of the company's stock valued at $80,000 after buying an additional 6,161 shares in the last quarter. Institutional investors own 64.84% of the company's stock.

Wall Street Analyst Weigh In

Separately, JMP Securities initiated coverage on shares of Werewolf Therapeutics in a research report on Wednesday, April 3rd. They set a "mkt outperform" rating and a $12.00 price objective for the company.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.